PR Newswire Clinical TrialsOriginal article
Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD
Phase 1positiveudenafilPositive
AI Analysis
Summary
Mezzion Pharma announced positive in vivo results for udenafil, a PDE5 inhibitor, in a preclinical autosomal dominant polycystic kidney disease model.
Clinical Trial Data
Phase
preclinical
Primary Endpoint
Met
Outcome Details
Positive in vivo results in preclinical ADPKD model
Importance:4/10
Sentiment:
0.70
ADPKDPDE5 inhibitorpreclinicalin vivo study
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 2, 2026 3:13 PM